REGENERON PHARMACEUTICALS, INC. (REGN)

As of 31 August 2026, short interest in REGN is 2,552,029 shares, down 833,812 shares over the last month. Over the last 48 readings it ranged from 1,715,921 shares (15 October 2024) to 3,501,203 shares (15 July 2026). At the reported average volume of 663K shares a day that is 3.9 days to cover.

<iframe src="https://xoomar.com/embed/stocks/regn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of REGN volume is 46.5%, down 18.0 points over the last five sessions. Over the last 52 readings it ranged from 35.2% (23 July 2026) to 75.9% (14 July 2026). The latest reading is 6.5 points below the 30-session average of 53.0%, on 146K shares reported.

As of 14 August 2026, the fails-to-deliver balance in REGN is 60 shares, down 1,384 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (30 January 2026) to 3,890 shares (4 February 2026). The latest reading sits at the bottom of that range.

Insiders at REGN reported 5 open-market sells worth $3.3M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: McCourt Marion (EVP Commercial) on 2026-09-03.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

5 Form 144 notices on file for REGN worth $3.3M at the prices reported; 5 in the last 90 days worth $3.3M. Latest: McCourt Marion filed on 2026-09-03 to sell 1,131 shares ($969K) from 2026-09-03.

2 holders above 5% have filed on REGN, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.4% of the class (7,660,810 shares), filed 2026-04-30 for an event on 2026-03-31.

8 of the 30 tracked managers held REGN at their latest 13F, $1.78B in total at quarter-end prices. AQR Capital Management is the largest at $702.2M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) REGENERON PHARMACEUTICALS, INC. reported revenue of $4.29B, up 16.7% from the same quarter a year earlier, and net income of $1.30B (12.23 diluted EPS). In FY 2025 it generated $4.98B of operating cash flow and spent $3.44B on buybacks and $370.3M on dividends. As of 2026-06-30, cash was $2.46B against $1.99B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2012-07-13 from the cover page.